Cutting-edge biotech investing in Asia

mp°a is a boutique healthcare advisory

• helping investors grow resilient healthcare platforms across Asia

Corporate development leader (Big pharma M&A / NASDAQ biotech hands on expertise) now based in Singapore.

• Operators eye for detail: Big Pharma / NASDAQ Corp. Dev. lead, combining deep science depth with hard-won BD and M&A experience

• Investor-grade judgement: turn complex clinical and commercial data into clear, investable theses from clinical to early commercial 

• Asia/China bridge: fluent in both Western governance expectations and Asian deal culture, helping global capital back Asia-origin innovation

• Value creation partner: help investors and CEOs design partnerships, structures and governance that improve exit quality and risk-adjusted returns

• Future pipeline lens: work with early-stage companies and VCs to build today in ways that will withstand scrutiny from tomorrow's growth and crossover investors

I help investors source, structure, and de-risk healthcare deals from clinical to early commercial, with selective involvement at seed where it builds future pipeline

In practice, this means:

• Improving risk-adjusted returns by avoiding scientific and BD pitfalls in Asia

• Turning technically strong but commercially under-positioned assets into credible candidates for global strategic or IPO exit

• Reducing execution risk when moving China / Asia assets into Singapore or global-ready structures

Deep understanding of Asia-  and China-origin innovation and regional sensitivities

With almost a decade of experience in Corporate Development and Corporate Finance and scientific training (PhD Imperial College London) with a particular focus on Asia, I am now based in Singapore, helping leading investors turn complex healthcare science into durable, compounding value creation across regions.

Over the past decade, I have led corporate development and BD at a global pharmaceutical company and a NASDAQ-listed clinical stage biotech, working on transactions across therapeutic areas and next-generation modalities.

That has meant evaluating clinical and commercial risk, structuring partnerships with Big Pharma, and helping boards navigate the trade-offs between dilution, control and long-term value.

Today I am anchoring in Singapore to focus on one question:

• How can global and regional capital best back Asia's most promising assets & innovation and meet/ exceed world-class governance standards?

My work sits at the intersection of science, strategy and structure: sourcing and diligencing assets, shaping BD narratives, and designing deal terms that work for investors and operators.

If you share my ambition for Singapore and Asia's role in global healthcare investing, please get in touch. I would be glad to explore how I can help you on your journey

Singapore is now in a scale-up phase: moving from building infrastructure and research to compounding returns from assets, platforms and regional partnerships in Asia.

Why am I based in Singapore?

• a neutral hub for Asia and global capital 
• with strong sovereign and independent platforms active and established
• and clear talent base and own focus on AI drug discovery and oncology

My edge:

• moving wider Asia and China innovation into structures and geographies that work for global growth and crossover capital

My immediate priority is to

• help leading investors build, refine, and execute on their investment thesis (growth / crossover / sovereign / large family offices)

• In parallel, I continue to mentor and selectively support earlier-stage founders & companies (particularly in immunology, oncology, and AI-enabled discovery). 

• Over time, I intend to develop an early-stage investment (growth & impact)  thesis that allows a meaningful portion of my economics to flow into serving underprivileged communities in Asia

General 

• From seed to crossover: a playbook for taking Asia biotech to global fund-grade governance and scale
• Question the herd: Why growth investors are prone to screen out hidden gems 
• Funding AI drug discovery - Or how not to lose your money ! - the edge isn't what you think it is, (a regular quarterly update)

China / Asia

• The China BD hangover - why lightning-speed, and deal discounts come with severe headaches.
• China Offshore NewCos - Why they fix some issues but not the core ones  - in-depth review
• The race to IND - why "first" isn't always first and what really matters to western pharma 
• Between terms sheets and tea houses - why western companies misunderstand their partners (a guide to informal relationships, reciprocity and unwritten commitment)

Singapore focused

• Singapore doesn't need its own version of Amgen, or does it? -
• Singapore, Not Boston! - what's the catch? and why the city-state is poised to play a much bigger role in biotech's future
• Singapore - trusted nation in the middle - how long-term vision created an ecosystem ideal to succeed in an increasingly fragmented world 

Have questions or exploring how I could support your healthcare investing strategy?

If you are a healthcare or diversified investor exploring how to deepen your exposure and expertise, I'm happy to meet for an initial discussion.

If you sit slightly earlier in the investment landscape and you or one of your portfolio companies need ad-hoc strategic advisory services, please get in touch and I'll respond as soon as I can.